Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13981330 | 0.94 | KDM4E (0.50) | MEN1KMT2AL3MBTL1LMNAHTT | |
| SCHEMBL15275317 | 0.94 | KDM4E (0.50) | MEN1KMT2AL3MBTL1LMNAHTT | |
| SCHEMBL18127062 | 0.94 | KDM4E (0.50) | MEN1KMT2AL3MBTL1LMNAHTT | |
| SCHEMBL10824702 | 0.91 | KMT2A (0.59) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL12089422 | 0.90 | MEN1 (0.56) | MEN1KMT2AL3MBTL1LMNAHTT | |
| SCHEMBL12855509 | 0.86 | KMT2A (0.45) | MEN1KMT2AL3MBTL1LMNAHTT | |
| SCHEMBL25607224 | 0.85 | APP (0.56) | KMT2AL3MBTL1RXRARXRBRAB9A | |
| SCHEMBL18126830 | 0.85 | KMT2A (0.51) | MEN1KMT2AL3MBTL1LMNAHTT | |
| SCHEMBL14579974 | 0.85 | MEN1 (0.62) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL10593412 | 0.85 | MEN1 (0.62) | MEN1KMT2AL3MBTL1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-12-12 | — | — | US | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230174520-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| WO-2023096987-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | TEON THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220267352-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-25 | — | — | US | disclosed |
| WO-2022120207-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-05-19 | — | — | US | disclosed |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090076088-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-19 | — | — | US | disclosed |
| US-20090076088-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-19 | — | — | US | disclosed |
| US-20090069383-A1 | Thrombin Receptor Antagonists | SCHERING CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-7488742-B2 | Thrombin receptor antagonists | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488742-B2 | Thrombin receptor antagonists | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | MEN1 1757/4885KMT2A 1600/4885L3MBTL1 3442/4885 |
| US-20230174520-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, ARRB1 | MEN1 3999/4885KMT2A 2715/4885L3MBTL1 3714/4885 |
| US-20090076088-A1 | Thrombin Receptor Antagonists | CNR1, CNR2, TBXA2R | MEN1 3544/4885KMT2A 4013/4885L3MBTL1 4669/4885 |
| US-20220267352-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | MEN1 241/4885KMT2A 3977/4885L3MBTL1 1577/4885 |
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | MEN1 431/4885KMT2A 1476/4885L3MBTL1 423/4885 |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | MEN1 431/4885KMT2A 1476/4885L3MBTL1 423/4885 |
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | MEN1 4350/4885KMT2A 2575/4885L3MBTL1 3210/4885 |
| US-20040152736-A1 | Thrombin receptor antagonists | CNR1, TBXA2R, CNR2 | MEN1 3101/4885KMT2A 4099/4885L3MBTL1 4370/4885 |
| US-20090069383-A1 | Thrombin Receptor Antagonists | CNR1, CNR2, TBXA2R | MEN1 3544/4885KMT2A 4013/4885L3MBTL1 4669/4885 |
| US-11819476-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | MEN1 286/4885KMT2A 3789/4885L3MBTL1 2979/4885 |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | MEN1 1368/4885KMT2A 2887/4885L3MBTL1 4245/4885 |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | MEN1 3578/4885KMT2A 3273/4885L3MBTL1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.